IDO1 and melanoma: Holmgaard et al. evaluated the combination of CTLA-4 blockade and IDO inhibition in the B16 melanoma mouse model, and data suggested that IDO inhibition can be employed to boost the effectiveness of immunotherapies in melanoma patients by augmenting T cell response.